Latest News

Dow Jones Newswires: AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints


AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with Faslodex combined with a placebo in a Phase 3 trial in advanced hormone receptor-positive breast cancer.

The Anglo-Swedish pharma giant


said the trial met both primary endpoints of improving progression-free survival in the overall patient population and in a prespecified biomarker subgroup of patients whose tumors had qualifying alterations.

The trial will continue to assess overall survival as a key secondary endpoint, it said.

Breast cancer is the most common cancer in the world with an estimated 2.3 million patients diagnosed in 2020.

Write to Kyle Morris at

Dow Jones Newswires: Reckitt Benckiser Q3 sales rise 14% to £3.74 billion

Previous article

Dow Jones Newswires: Iberdrola backs profit guidance after 9 month earnings rise

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News